Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 1—January 2015

Clinical, Environmental, and Serologic Surveillance Studies of Melioidosis in Gabon, 2012–2013

W. Joost Wiersinga1Comments to Author , Emma Birnie1, Tassili A.F. Weehuizen, Abraham S. Alabi, Michaëla A.M. Huson, Robert A. G. Huis in ’t Veld, Harry K. Mabala, Gregoire K. Adzoda, Yannick Raczynski-Henk, Meral Esen, Bertrand Lell, Peter G. Kremsner, Caroline E. Visser, Vanaporn Wuthiekanun, Sharon J. Peacock, Arie van der Ende, Direk Limmathurotsakul, and Martin P. Grobusch
Author affiliations: University of Amsterdam, Amsterdam, the Netherlands (W.J. Wiersinga, E. Birnie, T.A.F. Weehuizen, M.A.M. Huson, R.A.G. in ’t Veld, C.E. Visser, A. van der Ende, M.P. Grobusch); Albert Schweitzer Hospital, Lambaréné, Gabon (A.S. Alabi, H.K. Mabala, G.K. Adzoda, M. Esen, B. Lell, P.G. Kremsner, M.P. Grobusch); Ex-Situ Silex Geoarchaeology, Leiden, the Netherlands (Y. Raczynski-Henk); University of Tübingen, Tübingen, Germany (M. Esen, B. Lell, P.G. Kremsner, M.P. Grobusch); Mahidol University, Bangkok, Thailand (V. Wuthiekanun, D. Limmathurotsakul); University of Cambridge, Cambridge, UK (S.J. Peacock)

Main Article

Table 1

Antimicrobial drug susceptibility of Burkholderia pseudomallei and B. thailandensis strains from Gabon, 2012–2013*

Drug MIC, mg/L
Break point resistance B. pseudomallei patient strain B. pseudomallei soil strain C2 B. thailandensis soil strain D50
Amikacin 4† 96 96 128
Tobramycin 4† 16 24 24
Ciprofloxacin 1 0.75 1.0 0.5
Moxifloxacin 1‡ 0.75 0.75 0.75
Meropenem 4 0.75 0.75 0.75
Ceftazidime 8 2 2 2
TMP/SMX 1/19 1 1 1
AMC 8/2 4 4 6
TZP 32/?§ 1.5 1.5 3
Chloramphenicol 8 3 3 3
Tetracycline 1.5 2 8
Polymyxin B NA# >1,024 >1,024 >1,024

*Bacterial isolates were tested for their susceptibility to antimicrobial agents. MIC (MICs; mg/L) were determined by E-test on Mueller-Hinton-agar. When available break points were defined as described [19]. AMC, amoxicillin/clavulanic acid; NA, not applicable; TMP/SMX, trimethoprim/sulfamethoxazole, TZP, piperacillin/ tazobactam.
†Break point for gentamicin was used.
‡Break point for ciprofloxacin was used.
§Break point available for piperacillin only.
¶Break point for doxycycline was used.
#Intrinsic resistance.

Main Article

1These authors contributed equally to this article.

Page created: December 17, 2014
Page updated: December 17, 2014
Page reviewed: December 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.